Physician profile
Loren Chen
NPI 1992932917
$743.99
in general payments reported to CMS, 2019-2025
18 companies · $339 in 2025
The $339 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $32.42 · 2023: $181 · 2024: $192 · 2025: $339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $712.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $711.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $157.39 | 2024-2025 | Ams 700, Lux-Dx Insertable Cardiac Monitor |
| Sumitomo Pharma America, INC. | $86.79 | 2025 | Gemtesa |
| Pfizer INC. | $81.13 | 2024-2025 | |
| Exact Sciences Corporation | $79.32 | 2023-2024 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $32.68 | 2022-2023 | Recorlev |
| Bayer Healthcare Pharmaceuticals INC. | $30.79 | 2023 | |
| Biogen, INC. | $27.90 | 2025 | Spinraza |
| Novo Nordisk INC | $26.57 | 2025 | Wegovy |
| Janssen Biotech, INC. | $25.74 | 2024 | Stelara |
| Caris Mpi, INC. | $25.05 | 2025 | Mi Cancer Seek |
| Regeneron Healthcare Solutions, INC. | $24.29 | 2025 | Dupixent |
| Watermark Medical, INC. | $22.70 | 2024 | |
| Sanofi-Aventis U.S. LLC | $22.20 | 2023 | |
| Bausch Health US, LLC | $21.90 | 2023 | Wellbutrin |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.89 | 2025 | Jardiance |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $20.22 | 2023 | Heplisav-B |
| Glaxosmithkline, LLC. | $20.02 | 2022 | |
| Antares Pharma, INC. | $17.41 | 2023 | Xyosted, Tlando, Nocdurna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Loren Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.